We hope you enjoy this slid­edeck sup­port­ing a fas­ci­nat­ing, for­ward-look­ing ses­sion held at the 2019 Sharp­Brains Vir­tu­al Sum­mit: The Future of Brain Health (March 7–9th).  Full record­ings are avail­able for pur­chase here.

10.45am-12.15pm. How to inter­vene ear­ly: Exam­ples in depres­sion, epilep­sy and smok­ing ces­sa­tion 

• Dr. Wal­ter Green­leaf, Research Sci­en­tist at Stan­ford University’s Vir­tu­al Human Inter­ac­tion Lab
• David B. Klein, CEO of Click Ther­a­peu­tics
• Ana Maiques, CEO of Neu­ro­electrics
• Chaired by: Avery Bedows, Neu­rotech­nol­o­gy Spe­cial­ist at Loup Ven­tures

___

Sanofi Backs Click Ther­a­peu­tics as Dig­i­tal Med­i­cines Gain Momen­tum (Xcon­o­my):

“Drug mak­ers are mak­ing more bets on the nascent field of dig­i­tal med­i­cine. The lat­est exam­ple: Click Ther­a­peu­tics announced Mon­day that it grabbed a $17 mil­lion invest­ment led by Sanofi Ven­tures, the Cam­bridge, MA-based ven­ture cap­i­tal arm of the French phar­ma­ceu­ti­cal giant. Read the rest of this entry »

——–

Click Ther­a­peu­tics™ Reports Pre­lim­i­nary Results of a 416-Par­tic­i­pant Clin­i­cal Study Demon­strat­ing Excep­tion­al Engage­ment and Effi­ca­cy of Click­o­tine®, a Patent-Pend­ing Dig­i­tal Ther­a­peu­tics™ Pro­gram for Smok­ing Ces­sa­tion (press release):

“Click Ther­a­peu­tics, Inc. (“Click”), a com­pa­ny devel­op­ing a suite of per­son­al­ized data-dri­ven dig­i­tal ther­a­peu­tics for chron­ic health con­di­tions, announces today pre­lim­i­nary results of its ful­ly remote clin­i­cal tri­al of Click­o­tine, a dig­i­tal pro­gram designed for smok­ing ces­sa­tion. Read the rest of this entry »